SCHEMBL8773968

SCHEMBL8773968

CCc1ccccc1CS(=O)(=O)Cl

nearest known ligand 0.42

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 2/20 0.39
GABRB2 P47870 2/20 0.39
CTSB P07858 1/20 0.39
PSIP1 O75475 1/20 0.38
KMT2A Q03164 1/20 0.37
MGLL Q99685 1/20 0.36
ALDH1A1 P00352 4/20 0.36
HSD17B10 Q99714 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
MAPT P10636 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
LMNA P02545 1/20 0.34
POLB P06746 1/20 0.34
TSHR P16473 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30353838 0.91 ALDH1A1 (0.42) KMT2AALDH1A1HSD17B10TDP1MAPT
SCHEMBL11039359 0.91 ALDH1A1 (0.42) KMT2AALDH1A1HSD17B10TDP1MAPT
SCHEMBL776395 0.81 GABRA1 (0.42) GABRA1GABRB2CTSBPSIP1KMT2A
SCHEMBL27453156 0.80 PNMT (0.46) ALDH1A1HSD17B10TDP1MAPT
SCHEMBL15621620 0.80 FAAH (0.35) KMT2AALDH1A1HSD17B10TDP1MAPT
SCHEMBL1428960 0.80 ALDH1A1 (0.47) KMT2AALDH1A1LMNAPOLBTSHR
SCHEMBL9256894 0.79 GABRA1 (0.41) GABRA1GABRB2CTSBPSIP1MGLL
SCHEMBL5963 0.77 ALDH1A1 (0.55) KMT2AALDH1A1HSD17B10MAPTLMNA
SCHEMBL3316536 0.77 GABRA1 (0.39) GABRA1GABRB2CTSBPSIP1MGLL
SCHEMBL11365142 0.77 GABRA1 (0.50) GABRA1GABRB2CTSBPSIP1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240417379-A1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO., LTD (JP) 2024-12-19 US disclosed
US-12116351-B2 P2X4 receptor antagonist NIPPON CHEMIPHAR CO., LTD (JP) 2024-10-15 US disclosed
US-20220380322-A1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO., LTD (JP) 2022-12-01 US disclosed
US-11434207-B2 P2X4 receptor antagonist NIPPON CHEMIPHAR CO., LTD (JP) 2022-09-06 US disclosed
CN-108863959-B P2X4 receptor antagonists 日本化学药品株式会社 2021-11-30 CN disclosed
US-20200223806-A1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO., LTD (JP) 2020-07-16 US disclosed
CN-111333588-A P2X4 receptor antagonists 日本化学药品株式会社 2020-06-26 CN disclosed
US-10633349-B2 P2X4 receptor antagonist NIPPON CHEMIPHAR CO., LTD (JP) 2020-04-28 US disclosed
CN-104066724-B P2X4 receptor antagonists 日本化学药品株式会社 2020-04-17 CN disclosed
CN-110483423-A P2X4 receptor antagonist NIPPON CHEMIPHAR CO 2019-11-22 CN disclosed
CN-108863959-A P2X4 RECEPTOR ANTAGONIST 日本化学药品株式会社 2018-11-23 CN disclosed
US-20180201587-A1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO., LTD (JP) 2018-07-19 US disclosed
US-9969700-B2 P2X4 receptor antagonist NIPPON CHEMIPHAR CO., LTD. (JP) 2018-05-15 US disclosed
EP-2803662-B1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO (JP) 2017-03-01 EP disclosed
US-20160280667-A1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO., LTD (JP) 2016-09-29 US disclosed
US-9382236-B2 P2X4 receptor antagonist NIPPON CHEMIPHAR CO., LTD (JP) 2016-07-05 US disclosed
US-20140357858-A1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO., LTD (JP) 2014-12-04 US disclosed
EP-2803662-A1 P2X4 RECEPTOR ANTAGONIST Nippon Chemiphar Co., Ltd. (JP) 2014-11-19 EP disclosed
CN-104066724-A P2X4 receptor antagonists NIPPON CHEMIPHAR CO 2014-09-24 CN disclosed
EP-0805159-A1 Phosphorus containing alkyl or arylsulphonyl derivatives and method for preparing same Cytec Canada Inc. (CA) 1997-11-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220380322-A1 P2X4 RECEPTOR ANTAGONIST P2RX7, P2RX1, P2RX2 GABRA1 216/4885GABRB2 274/4885CTSB 3710/4885
US-20240417379-A1 P2X4 RECEPTOR ANTAGONIST P2RX7, P2RX1, P2RX2 GABRA1 194/4885GABRB2 220/4885CTSB 3837/4885
US-12116351-B2 P2X4 receptor antagonist P2RX7, P2RX1, P2RX2 GABRA1 216/4885GABRB2 274/4885CTSB 3710/4885
US-20160280667-A1 P2X4 RECEPTOR ANTAGONIST P2RX7, P2RX1, P2RX2 GABRA1 208/4885GABRB2 264/4885CTSB 3707/4885
US-20140357858-A1 P2X4 RECEPTOR ANTAGONIST P2RX7, P2RX1, P2RX2 GABRA1 216/4885GABRB2 274/4885CTSB 3710/4885
US-20200223806-A1 P2X4 RECEPTOR ANTAGONIST P2RX7, P2RX1, P2RX2 GABRA1 216/4885GABRB2 274/4885CTSB 3710/4885
US-11434207-B2 P2X4 receptor antagonist P2RX7, P2RX1, P2RX2 GABRA1 216/4885GABRB2 274/4885CTSB 3710/4885
US-10633349-B2 P2X4 receptor antagonist P2RX7, P2RX1, P2RX2 GABRA1 216/4885GABRB2 274/4885CTSB 3710/4885
US-20180201587-A1 P2X4 RECEPTOR ANTAGONIST P2RX7, P2RX1, P2RX2 GABRA1 216/4885GABRB2 274/4885CTSB 3710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.